Evaluation of Glycemic Control with EndoTool Glucose Management System for Insulin Infusion Therapy


This retrospective review compares glycemic control with EndoTool to a traditional insulin infusion protocol for critically-ill patients.


371-bed full-service community medical center.

  • Median time to control (first recorded blood glucose <150 mg/dL) decreased 30.9% with EndoTool, from 7 hours 50 minutes to 5 hours 25 minutes.
  • Time in the target range of 100-150 mg/dL mg/dL increased 19.0% with EndoTool, from 50.6% to 60.2%.
  • Incidence of hypoglycemia <70 mg/dL decreased 70.3% with EndoTool, from 41.4% to 12.3% of patients.
  • Incidence of hypoglycemia <50 mg/dL decreased 84.7% with EndoTool, from 26.8% to 4.1% of patients.
  • Median ICU length of stay decreased by 2 full days with EndoTool, from 6 days to 4 days.
  • Median hospital length of stay decreased by 4 full days with EndoTool, from 12 days to 8 days.

EndoTool should be the standard of care for management of patients receiving continuous infusion insulin, given its ability to achieve significant reductions in time to control, hypoglycemia and length of stay as well as a greater percent of time in the target blood glucose range.


Lauren Igneri, PharmD, BCPS, BCCCP; Alan Schorr, DO, FAAIM, FACE; Patricia Gilbert, MSN, RN; Katherine Krol, BSN, CCRN; Brandon Kim, PharmD; Jessica Ellis, PharmD; Suzette Cunicelli, RPh; Benjamin Solomon, MD.


Presented at American College of Clinical Pharmacy Global Conference and Society of Critical Care Medicine Critical Care Congress. Published in Journal of the American College of Clinical Pharmacy, Volume 1, Issue 2, p122-353 and Critical Care Medicine, Volume 44, Issue 12, p197.